# Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

> **NCT02504372** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1177 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02504372
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-06
- **Primary completion:** 2023-01-24
- **Final completion:** 2026-01-21
- **Target enrollment:** 1177 (ACTUAL)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504372, "Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02504372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*